-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XTX-301 in Triple-Negative Breast Cancer (TNBC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XTX-301 in Triple-Negative Breast Cancer (TNBC) Drug Details: XTX-301 is under development for treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XTX-301 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XTX-301 in Colorectal Cancer Drug Details: XTX-301 is under development for treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XTX-301 in Endometrial Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XTX-301 in Endometrial Cancer Drug Details: XTX-301 is under development for treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XTX-301 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XTX-301 in Ovarian Cancer Drug Details: XTX-301 is under development for treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XTX-301 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XTX-301 in Solid Tumor Drug Details: XTX-301 is under development for treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XTX-301 in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XTX-301 in Pancreatic Cancer Drug Details: XTX-301 is under development for treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XTX-301 in Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XTX-301 in Melanoma Drug Details: XTX-301 is under development for treatment of solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XTX-301 in Prostate Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XTX-301 in Prostate Cancer Drug Details: XTX-301 is under development for treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XTX-301 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XTX-301 in Non-Small Cell Lung Cancer Drug Details: XTX-301 is under development for treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – XTX-301 in Head And Neck Squamous Cell Carcinoma (HNSC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. XTX-301 in Head And Neck Squamous Cell Carcinoma (HNSC) Drug Details: XTX-301 is under development...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.